No abstract available.
Immunoenzyme Techniques*

No abstract available.
Fluoroimmunoassay* ; Immunoenzyme Techniques*

338 subjects at the age of 17-49 were undergone EIA test. Results showed an increasing trend in Chlamydia trachomatis infection. Clinical manifestations were not detected. The incidence is highest at the age of 17-26 (14.68%), 17-36 (10.67%). In the groups of genital tract inflamation, of uterine neck, of vaginitis the incidence reaches 2.7%, 12.71% and 12.50% respectively
Chlamydia trachomatis ; Immunoenzyme Techniques ; Women

No abstract available.
Immunoenzyme Techniques* ; Mycobacterium tuberculosis* ; Mycobacterium*

At the summer workshop of the Korean Endocrine Society held in 2016, some examples of protein experiments were discussed in the session entitled “All about working with proteins.” In contrast to what the title suggested, it was unrealistic to comprehensively discuss all protein analytical methods. Therefore, the goal was to outline protein experimental techniques that are useful in research or in bench work. In conversations with clinicians, however, I have always felt that researchers who do not engage in bench science have different demands than those who do. Protein research tools that are useful in bench science may not be very useful or effective in the diagnostic field. In this paper, I provide a general summary of the protein analytical methods that are used in basic scientific research, and describe how they can be applied in the diagnostic field.
Chromatography ; Education ; Immunoenzyme Techniques ; Methods* ; Molecular Imaging

BACKGROUND: The hepatitis B surface antibody (anti - HBs) level has been used as an indicator for protective immunity after vaccination. Various kinds of assay systems including EIA (Enzyme Immunoas-say) and MEIA (Microparticle enzyme immunoassay) have been used for the quantification of that antibody. Although most anti - HBs assay systems have been standardized based on the WHO reference preparations, and results of the assay systems are in good agreement for most of the serums that were examined, some discrepancies in the cases have been observed among the various assay systems. In this study, four kinds of anti - HBs assay systems were compared for relative qualitative and quantitative results based on mIU/mL unit. METHODS: Serum samples from five hundred visitors to the Health Care Center, Seoul Paik Hospital were assayed by Cobas Core Anti-HBs Quant EIA II (Roche), Enzygost Anti-HBs II (DADE Behring), AxSYM AUSAB (Abbott) and Elecsys Anti-HBs (Roche). RESULTS: The concordance rates among the 4 assay kits were 92.8% (464/500) and 75.6% (378/500) was positive (anti - HBs > or =10 mIU/mL) and 17.2% (86/500) were negative. Among 36 samples (7.2%) showing discrepant results, 23 samples (4.6%) were negative by AxSym or Behring or both and positive by Elecsys or Cobas Core or both. Most of the discrepant samples showed low-level reactive results in the range of 10 to 100 IU/L for the other assay kits, which showed positive results. Quantitative agreements between 2 assay systems gave linear correlation coefficients ranging from CONCLUSIONS: The quantification of anti - HBs can show various results according to the kind of assay kit used. Samples showing relatively low reactive results in the range of 10 to 100 mIU/mL when tested by Elecsys or Cobas Core should be especially interpreted cautiously because those same samples might be negative when tested by Behring or AxSYM.
Delivery of Health Care ; Hepatitis B* ; Hepatitis* ; Immunoenzyme Techniques ; Seoul ; Vaccination

BACKGROUND: Instead of hepatitis C virus (HCV) RNA test using RT-PCR, an enzyme immunoas-say for detection of HCV core protein as a simple, rapid method for the detection of HCV viremia has been developed recently. In this study, we investigated the usefulness of HCV core protein for the detection of HCV viremia by comparing the results of HCV RNA. METHODS: The study group included 71 patients; some of whom showed anti-HCV Ab. The HCV core protein assay was performed by enzyme immunoassay (Ortho Clinical Diagnostics, Raritan, NJ, USA). RESULTS: The concordance rate between HCV RNA and HCV core protein assay was 75%. Compared with the HCV RNA results, HCV core protein assay showed 50% sensitivity and 97% specificity. Among 17 patients whose results for HCV RNA were positive and those of HCV core protein were negative, all of them had anti-HCV Ab. CONCLUSIONS: Although the sensitivity of HCV core protein was not high in cases with anti-HCV Ab, the positive results for HCV core protein suggests the presence of HCV viremia. So, HCV core protein may be used as a simple and rapid method for detection of HCV viremia.
Hepacivirus ; Humans ; Immunoenzyme Techniques ; RNA ; Sensitivity and Specificity ; Staphylococcal Protein A ; Viremia*

The aim of this study was to evaluate domestic enzyme immunoassay(EIA) kit ?LG HCD 3.0?(LG) for the detection of antibody to hepatitis C virus(anti-HCV) in comparision with Axsym HCV version 3.0(Axsym), Cobas Core anti-HCV EIA(Cobas). Cobas kit shows better clear distinction between positive and negative by signal/cutoff ratio(S/C), but it also reveal relatively high false positive rate. The concordance rate of test results between LG and Axsym was 96.2%, between LG and Cobas was 95.5%, and total agreement between three EIA kit was 93.9%. LG were relative poor distinction between positive and negative results, but it could be applied clinically as a screening tool for hepatitis C in general population. The S/C of one false negative result by LG was 0.91, and false positive were less than 4.0, therefore we concluded it is necessary to confirm by immunoblotting assay when S/C were between 0.8 and 4.0.
Hepacivirus ; Hepatitis C ; Immunoblotting ; Immunoenzyme Techniques* ; Mass Screening

BACKGROUND: The purpose of this study was to evaluate the newly improved third generation enzyme immunoassay kit, LG HCD 3.0TMB (LG Chemical Ltd., Korea) for the detection of antibodies for the hepatitis C virus. METHODS: The 1,068 clinical samples and 3 seroconversion panels were subjected to compare LG HCD 3.0TMB with Ortho HCV 3.0. The discordant clinical samples were confirmed by RT-PCR (Roche Amplicor HCV test) and RIBA (LG HCD confirm, Ortho RIBA HCV 3.0). Reproducibility was estimated using six samples with different anti-HCV levels for each assay. RESULTS: In clinical samples, concordance between LG HCD 3.0TMB and Ortho HCV 3.0 was 98.8% (1,055 of 1,068 tests) in the screening test. After a repeat test of 13 discordant samples, overall concordance was 99.3% (1,061 of 1,068 tests). In the seroconversion panel testing, the LG HCD 3.0TMB detected HCV antibodies earlier than the Ortho HCV 3.0 in one of the three panels. Results of both EIA assays were constant on the reproducibility test. CONCLUSIONS: Based on the good agreement with Ortho HCV 3.0 and superior seroconversion sensitivity, the LG HCD 3.0TMB assay appears to be suitable for detecting HCV antibodies in clinical laboratories.
Antibodies ; Hepacivirus ; Hepatitis C Antibodies* ; Immunoenzyme Techniques ; Mass Screening

BACKGROUND: The test for the anti-rubella IgM Ab (R-IgM) is important in early pregnancies because therapeutic termination may be considered depending on the results. METHODS: The subjects consisted of 52 pregnant women with positive or equivocal R-IgM by Cobas Core Anti-Rubella IgM EIA test (Roche, Basel, Swiss) between January 1997 and July 2000. Three different EIA methods such as the Enzygnost Anti-Rubella-virus/IgM test (DADE Behring, Marburg, Germany), the AxSYM Anti-Rubella IgM test (Abbott, USA), and the IMx Anti-Rubella IgM test (Abbott, USA) were simultaneously performed on 44 specimens as well as the Cobas Core Anti-Rubella IgM EIA test. RESULTS: Among 52 pregnancies, 9 (17%) experienced an artificial abortion due to positive or equivocal R-IgM result. The clinical symptoms associated with rubella infection were observed in 3 cases and the persistent R-IgM positivity was noted for more than 1 year in 4 cases. The concordance rate between 4 different EIAs was 41%. When performed with serial diluted pool and 3 sera, the results of Cobas Core were similar to those of AxSYM, IMx and Enzygnost. The R-IgM were detected one titre higher in diluted sera performed by IMx and Enzygnost than those of Cobas Core and AxSYM. CONCLUSIONS: For pregnancies with positive or equivocal R-IgM, it is recommended that results should be interpreted with caution, considering the possibilities, such as a persistent R-IgM response and discrepant R-IgM depending on the different EIA methods.
Female ; Humans ; Immunoenzyme Techniques* ; Immunoglobulin M* ; Pregnancy* ; Pregnant Women ; Rubella